There has not been a change in the standard of care in this type of cancer in a decade, according to an expert from ASCO.
Cholangiocarcinoma
Latest News
February 21st 2022
By Mary Caffrey
Drugs targeting FGFR mutations, which are seen in patients with intrahepatic cholangiocarcinoma (CCA), have generated particular excitement; the authors note that prior to the approval of pemigatinib, the first targeted therapy approved by FDA, only 15% to 25% of patients with CCA were “fit enough to receive second-line chemotherapy.”
What Makes Recurrence More Likely After Hepatectomy in Intrahepatic Cholangiocarcinoma?
By Mary Caffrey
What Do Real-world Data Say About FGFR2 Status and PFS, OS in Cholangiocarcinoma?
By Mary Caffrey
Advertisement
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Senate Unveils Sweeping Bill to Reform 340B Drug Program
2
Gene Therapy for Wet AMD Near an Inflection Point: Arshad Khanani, MD
3
Brexpiprazole and Dextromethorphan-Bupropion: Mechanisms of Action and Key Clinical Trial Data for Approved Alzheimer's Disease Agitation Therapies
4
JAK Inhibitor Hesitancy and Step Therapy in Pediatric Alopecia Areata: A Q&A With Brittany Craiglow, MD
5